SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants.

Britton, KJ; Pickering, JL; Pomat, WS; de Gier, C; Nation, ML; Pell, CL; Granland, CM; Solomon, V; Ford, RL; Greenhill, A; et al. Britton, KJ; Pickering, JL; Pomat, WS; de Gier, C; Nation, ML; Pell, CL; Granland, CM; Solomon, V; Ford, RL; Greenhill, A; Hinds, J; Moore, HC; Richmond, PC; Blyth, CC; Lehmann, D; Satzke, C; Kirkham, L-AS; 10v13vPCV trial team (2021) Lack of effectiveness of 13-valent pneumococcal conjugate vaccination against pneumococcal carriage density in Papua New Guinean infants. Vaccine, 39 (38). pp. 5401-5409. ISSN 1873-2518 https://doi.org/10.1016/j.vaccine.2021.07.085
SGUL Authors: Hinds, Jason

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (746kB) | Preview
[img] Microsoft Word (.docx) (Supplementary material) Published Version
Available under License Creative Commons Attribution.

Download (32kB)

Abstract

BACKGROUND: Papua New Guinea (PNG) introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in 2014, with administration at 1, 2, and 3 months of age. PCV13 has reduced or eliminated carriage of vaccine types in populations with low pneumococcal carriage prevalence, carriage density and serotype diversity. This study investigated PCV13 impact on serotype-specific pneumococcal carriage prevalence, density, and serotype diversity in PNG infants, who have some of the highest reported rates of pneumococcal carriage and disease in the world. METHODS: Nasopharyngeal swabs were collected at 1, 4 and 9 months of age from PCV13-vaccinated infants (n = 57) and age-/season-matched, unvaccinated infants (at approximately 1 month, n = 53; 4 months, n = 57; 9 months, n = 52). Serotype-specific pneumococcal carriage density and antimicrobial resistance genes were identified by qPCR and microarray. RESULTS: Pneumococci were present in 89% of swabs, with 60 different serotypes and four non-encapsulated variants detected. Multiple serotype carriage was common (47% of swabs). Vaccine type carriage prevalence was similar between PCV13-vaccinated and unvaccinated infants at 4 and 9 months of age. The prevalence of non-vaccine type carriage was also similar between cohorts, with non-vaccine types present in three-quarters of samples (from both vaccinated and unvaccinated infants) by 4 months of age. The median pneumococcal carriage density was high and similar at each age group (~7.0 log10genome equivalents/mL). PCV13 had no effect on overall pneumococcal carriage density, vaccine type density, non-vaccine type density, or the prevalence of antimicrobial resistance genes. CONCLUSION: PNG infants experience dense and diverse pneumococcal colonisation with concurrent serotypes from 1 month of age. PCV13 had no impact on pneumococcal carriage density, even for vaccine serotypes. The low prevalence of vaccine serotypes, high pneumococcal carriage density and abundance of non-vaccine serotypes likely contribute to the lack of PCV13 impact on carriage in PNG infants. Indirect effects of the infant PCV programs are likely to be limited in PNG. Alternative vaccines with broader coverage should be considered.

Item Type: Article
Additional Information: © 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Carriage, Microarray, Papua New Guinea, Pneumococcal conjugate vaccine, Serotype, Streptococcus pneumoniae, 10v13vPCV trial team, 06 Biological Sciences, 07 Agricultural and Veterinary Sciences, 11 Medical and Health Sciences, Virology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Vaccine
ISSN: 1873-2518
Language: eng
Dates:
DateEvent
7 September 2021Published
9 August 2021Published Online
26 July 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
1173163National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
PubMed ID: 34384633
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113580
Publisher's version: https://doi.org/10.1016/j.vaccine.2021.07.085

Actions (login required)

Edit Item Edit Item